The therapeutic value of cannabinoids in MS: real or imaginary?

Editorial

Joep Killestein et al. Mult Scler. 2004 Aug.

. 2004 Aug;10(4):339-40.

doi: 10.1191/1352458504ms1064ed.

No abstract available

Comment on

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Vaney C, et al. Mult Scler. 2004 Aug;10(4):417-24. doi: 10.1191/1352458504ms1048oa. Mult Scler. 2004. PMID: 15327040 Clinical Trial.
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. Brady CM, et al. Mult Scler. 2004 Aug;10(4):425-33. doi: 10.1191/1352458504ms1063oa. Mult Scler. 2004. PMID: 15327041
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
Wade DT, Makela P, Robson P, House H, Bateman C. Wade DT, et al. Mult Scler. 2004 Aug;10(4):434-41. doi: 10.1191/1352458504ms1082oa. Mult Scler. 2004. PMID: 15327042 Clinical Trial.